Chairs: Gabriela Wiedemann & Aimee Merino
Title: Phase I Study of iPSC derived CAR-NK FT596 with Rituximab as Relapse Prevention After Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) for B-Cell Lymphoma (NCT04555811) (#170)
2:30 PM
Defining mechanisms of NK cell dysfunction in the multiple myeloma tumor microenvironment (#171)
2:35 PM
CD147-CAR-NK Cell Therapy Shows Minimal Toxicities in Human CD147 Transgenic Mouse Model with Solid Tumors (#172)
2:40 PM
ASB2 supports liver ILC1 maintenance and tumorcidal activities through balancing lipid metabolism (#173)
2:45 PM
Targeting the KRAS oncoprotein sensitizes pancreatic cancer to NK cell therapy (#174)
2:50 PM
Nur77 activation reinvigorates NK cell immunity in hepatocellular carcinoma (#175)
2:55 PM
Evidence for a Functional and Spatial Natural Killer Cell Dichotomy in Human Endometrial Cancer (#176)
3:00 PM
DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity (#177)
3:05 PM